Loading
A phase 1 trial of BP2202 run by BrightPath Biotherapeutics Co., Ltd., not yet recruiting.
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07667868 by BrightPath Biotherapeutics Co., Ltd., with 18 participants planned, started 2026-10-01. Conditions recorded: Relapsed/Refractory Multiple Myeloma (RRMM). Interventions recorded: BP2202.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/